↓ Skip to main content

Metformin monotherapy for type 2 diabetes mellitus

Overview of attention for article published in this source, July 2005
Altmetric Badge

Mentioned by

2 policy sources
2 tweeters
1 Wikipedia page


250 Dimensions

Readers on

171 Mendeley
4 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Metformin monotherapy for type 2 diabetes mellitus
Published by
John Wiley & Sons, Ltd, July 2005
DOI 10.1002/14651858.cd002966.pub3
Pubmed ID

Saenz, Antonio, Fernandez-Esteban, Inmaculada, Mataix, Angel, Ausejo Segura, Monica, Roqué i Figuls, Marta, Moher, David


Metformin is an anti-hyperglycaemic agent used for the treatment of type 2 diabetes mellitus. Type 2 diabetes may present long-term complications: micro- (retinopathy, nephropathy and neuropathy) and macrovascular (stroke, myocardial infarction and peripheral vascular disease). Two meta-analyses have been published before, although only secondary outcomes were assessed.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 171 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 3 2%
Brazil 3 2%
Italy 2 1%
United States 2 1%
Denmark 1 <1%
Ireland 1 <1%
Unknown 159 93%

Demographic breakdown

Readers by professional status Count As %
Student > Master 31 18%
Student > Bachelor 24 14%
Researcher 24 14%
Student > Ph. D. Student 21 12%
Other 17 10%
Other 38 22%
Unknown 16 9%
Readers by discipline Count As %
Medicine and Dentistry 108 63%
Agricultural and Biological Sciences 15 9%
Nursing and Health Professions 8 5%
Pharmacology, Toxicology and Pharmaceutical Science 6 4%
Neuroscience 1 <1%
Other 9 5%
Unknown 24 14%